| __timestamp | Bristol-Myers Squibb Company | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 205018000 |
| Thursday, January 1, 2015 | 3909000000 | 392709000 |
| Friday, January 1, 2016 | 4946000000 | 299694000 |
| Sunday, January 1, 2017 | 6066000000 | 397061000 |
| Monday, January 1, 2018 | 6547000000 | 434100000 |
| Tuesday, January 1, 2019 | 8078000000 | 782200000 |
| Wednesday, January 1, 2020 | 11773000000 | 1119900000 |
| Friday, January 1, 2021 | 9940000000 | 2437500000 |
| Saturday, January 1, 2022 | 10137000000 | 1560400000 |
| Sunday, January 1, 2023 | 10693000000 | 1815800000 |
| Monday, January 1, 2024 | 11949000000 | 1970500000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, cost management is crucial. Over the past decade, Bristol-Myers Squibb Company and Regeneron Pharmaceuticals, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Bristol-Myers Squibb's cost of revenue surged by approximately 172%, peaking in 2020 with a 30% increase from the previous year. In contrast, Regeneron Pharmaceuticals experienced a more modest growth of around 785% over the same period, with a notable spike in 2021, where costs more than doubled compared to 2020.
This divergence highlights the strategic differences between the two companies. While Bristol-Myers Squibb has consistently expanded its operations, Regeneron has shown a more volatile pattern, possibly reflecting its focus on innovation and new product development. As the pharmaceutical landscape evolves, these cost trends offer valuable insights into each company's operational strategies.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Incyte Corporation
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Regeneron Pharmaceuticals, Inc. vs Grifols, S.A.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Cytokinetics, Incorporated
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and MiMedx Group, Inc.